SHINE: Study design

Study design and patient characteristics

  • An open-label, re-dosing extension study in patients who previously participated in clinical studies of SPINRAZA® (ENDEAR, CHERISH, EMBRACE, CS12* or CS3a)1
  • Patients are diagnosed with infantile-onset (Type I) or later-onset (Type II/III) SMA1
  • All patients in SHINE are receiving SPINRAZA® 12-mg1
  • The study is ongoing

*Study CS12 involved re-dosing patients who had previously participated in studies CS1, CS2 and CS10.

Bill
age 48*Later-onset (Type III) SMA
treated with SPINRAZA®

*Age at time of photo shoot.

References:
1. SPINRAZA® Summary of Product Characteristics.